Global Expansion TriLink expanded its GMP enzyme manufacturing facility in Jupiter, Florida in 2026, signaling capacity growth and opportunities to supply larger-scale RNA production, capping services, and related nucleic acid materials to pharmaceutical and biotech customers.

Strategic Partnerships Recent collaborations and MoUs with Tebubio, IVI, Aldevron, and Avantor indicate a strong channel strategy and broader geographic reach (including Europe, Middle East and Africa), suggesting openings for co-developed kits, shared supply agreements, and expanded service footprints.

Product Leadership TriLink’s patented CleanCap mRNA capping technology and launched mRNA synthesis kit position the company as a go-to supplier for high-quality mRNA materials, enabling sales conversations around vaccine development, oncology, infectious disease, and neurodegenerative research.

Public Health Demand With a track record in supporting rapid vaccine initiatives and government partnerships, there are opportunities to pursue government contracts, supply agreements for pandemic preparedness, and collaboration on scalable mRNA solutions for global health programs.

Scale and Services Facility expansion combined with CDMO capabilities and ready-made materials creates cross-sell potential for customers seeking end-to-end nucleic acid solutions, from synthesis and capping to analytical services and custom material supply.